Physician profile
Michael Lambert
NPI 1598769549
$638.52
in general payments reported to CMS, 2019-2025
13 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.99 · 2021: $50.62 · 2022: $87.59 · 2023: $223 · 2024: $136 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $92.98 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $81.56 | 2021-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $78.86 | 2023-2025 | Benlysta |
| Calliditas Therapeutics US INC. | $62.80 | 2023-2025 | Tarpeyo |
| Amgen INC. | $60.89 | 2020-2023 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $58.26 | 2021-2024 | |
| Travere Therapeutics, INC. | $39.67 | 2023 | |
| Medtronic, INC. | $39.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.98 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $31.08 | 2021-2024 | Auryxia, Vafseo |
| Mallinckrodt Hospital Products INC. | $21.61 | 2024 | Terlivaz |
| Nxstage Medical, INC. | $18.56 | 2023 | Nxstage System One |
| Fresenius USA Marketing, INC. | $18.11 | 2025 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.